KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma.
|
| Abstract |
Lung cancer is the leading cause of all cancer deaths worldwide with suboptimal prognosis and treatment options. Therefore this study aimed to identify molecular characteristics with a predictive clinical utility which at the same time might represent novel therapeutic targets for human lung adenocarcinoma. Within this study mutations of v-Ki-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS), a gene frequently mutated in lung adenocarcinoma, and their association with enzymatic activities, as assessed by activity-based proteomics, of members of the serine hydrolase (SH) superfamily, a large class of enzymes that have previously been linked to cancer was investigated. The results revealed that the activity of myeloblastin was significantly altered in the lung adenocarcinoma biopsies harboring a KRAS gene mutation. In conclusion myeloblastin is a potential therapeutic target for human lung adenocarcinoma, indicating that the combination of activity-based proteomics with mutational analysis is a valid approach for the discovery of novel biomarkers.
|
|---|---|
| Authors | Thomas Wiedl, Stéphane Collaud, Sven Hillinger, Stephan Arni, Chris Burgess, Werner Kroll, Peter Schraml, Alex Soltermann, Holger Moch, Walter Weder |
| Journal | Cancer genomics & proteomics (Cancer Genomics Proteomics) Vol. 9 Issue 1 Pg. 51-4 (Jan 2012) ISSN: 1790-6245 [Electronic] Greece |
| PMID | 22210048 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!